OBJECTIVE： To observe the efficacy and safety of sodium valproate combined with levetiracetam in the treatment of post-stroke epilepsy. METHODS： 84 patients with post-stroke epilepsy were randomly divided into control group （42 cases） and observation group （42 cases） . All patients were given lowering lipid， lowering blood pressure， improving microcirculation， reducing intracranial pressure， anticoagulation， anti-platelet aggregation， cranial nerve protection and other conventional treatment， patients with status epilepticus were given stability control symptoms. Based on it， control group orally received Sodium valproate sustained-release tablet 15-20 mg/（kg·d）， 3 times a day， for 7 d， maintaining the dose if symptom was controlled； the dose increased to 20-30 mg/（kg·d） if it was not controlled， 3 times a day. Observation group was additionally received Levetiracetam tablet with initial dose of 0.25 g， twice a day， increased to 0.5 g after 7 d， maintaining the dose if symptom was controlled； then increased to 3 g if symptom was not controlled， twice a day. 2 groups of patients were continuous treated for 12 months， then decreased Levetiracetam tablet 0.25 g weekly until complete withdrawal， patients with recurrence required lifelong medication. The clinical observation， times of seizures， seizure duration， epileptiform discharges， involved lead number， serum neuron specific enolase （NSE）， TNF-α， IL-2 and IL-6 before and after treatment， the incidence of adverse reactions in 2 groups were observed. RESULTS： The total effective rate in observation group was significantly higher than control group， with statistical significance （P＜0.05）. Before treatment， there were no significant differences in the times of seizures， seizure duration， epileptiform discharges， involved lead number， NSE， TNF-α， IL-2 and IL-6 levels in 2 groups （P＞0.05）. After treatment， the times of seizures， seizure duration， epileptiform discharges， involved lead number， NSE， TNF-α， IL-2 and IL-6 levels in 2 groups were significantly lower than before， and observation group was lower than control group， with statistical significances （P＜0.05）. There was no significant difference in the incidence of adverse reactions in 2 groups （P＞0.05）. CONCLUSIONS： Based on conventional treatment， the efficacy of sodium valproate combined with levetiracetam is significantly superior to sodium valproate alone in the treatment of post-stroke epilepsy， and do not increase the indence of adverse reactions.